TENAX THERAPEUTICS
Tenax Therapeutics is a pharmaceutical company that focuses on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. Tenax Therapeutics develops novel dosing and formulations of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension. Imatinib, which acts on underlying cellular proliferative pathways linked to PAH, has the potential to be the first disease-modifying therapy for the disease.
TENAX THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
1967-01-01
Address:
Chapel Hill, North Carolina, United States
Country:
United States
Website Url:
http://www.tenaxthera.com
Total Employee:
11+
Status:
Active
Contact:
9198552133
Email Addresses:
[email protected]
Total Funding:
108.29 M USD
Technology used in webpage:
Euro Amazon CloudFront Fastly Amazon Ireland Region Webflow Level 3 Communications Webflow Hosting
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
ALung Technologies
ALung Technologies develops medical gas exchange devices for the treatment of acute and chronic respiratory disorders.
Nuo Therapeutics
Nuo Therapeutics develops biological therapies to address the areas of wound care, inflammation, and angiogenesis.
Echo Therapeutics
Echo Therapeutics develops the Symphony tCGM System, a novel, non-invasive (needle-free) glucose monitoring system for diabetes patients.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Intarcia Therapeutics
Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.
Sarepta Therapeutics
Sarepta Therapeutics focuses on the discovery and development of precision genetic medicine to treat rare diseases.
XOMA
XOMA is at the forefront of antibody discovery and development, one of the most powerful and transformative fields of drug innovation
Current Employees Featured
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-01-19 | PH Precision Med | PH Precision Med acquired by Tenax Therapeutics | N/A |
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2014-08-06 | Imperial College London | Tenax Therapeutics investment in Grant - Imperial College London | 500 K USD |
Official Site Inspections
http://www.tenaxthera.com Semrush global rank: 9.88 M Semrush visits lastest month: 298
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Tenax Therapeutics"
About Us – Tenax
From 2001-2008, Mr. Giordano served in sales and operational management roles at PPD, also a global clinical research organization, where his primary focus was biotechnology companies.See details»
Tenax Therapeutics - LinkedIn
Tenax Therapeutics | 3,384 followers on LinkedIn. Tenax Therapeutics is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies.See details»
Tenax Therapeutics - Crunchbase Company Profile & Funding
Tenax Therapeutics is a pharmaceutical company that focuses on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high …See details»
Tenax Therapeutics, Inc. - Executive Bio, Top Executies, and ...
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States.See details»
Tenax Therapeutics (TENX) Company Profile & Description
Jul 11, 2025 Company profile for Tenax Therapeutics, Inc. (TENX) stock, with a description, list of executives, contact details and other key facts.See details»
Investor Relations | Tenax Therapeutics
Mar 25, 2025 Tenax Therapeutics Investor relations (IR) website contains information about our business for stockholders, potential investors, and financial analysts.See details»
Tenax
What is PH-HFpEF? Pulmonary Hypertension (PH) resulting from Heart Failure with preserved Ejection Fraction (HFpEF) is a debilitating, often fatal disease. It’s the most common form of pulmonary hypertension globally. Yet, there are …See details»
A Brief History of Tenax Therapeutics – …
Dec 3, 2024 Continued Innovation and Research: Tenax Therapeutics remains dedicated to fostering a culture of innovation and research within the organization. By staying at the forefront of scientific advancements and technological …See details»
Tenax Therapeutics Company Profile - Office Locations ... - Craft
Oct 29, 2024 Tenax Therapeutics has 4 employees at their 1 location. See insights on Tenax Therapeutics including office locations, competitors, revenue, financials, executives, …See details»
Tenax Therapeutics Org Chart + Executive Team - The Official Board
The org chart of Tenax Therapeutics contains its 12 main executives including Christopher Giordano and Thomas Mcgauley.See details»
Committee Composition | Tenax Therapeutics
View the committee structure and board of director membership for Tenax TherapeuticsSee details»
Tenax Therapeutics (formerly Oxygen Biotherapeutics)
Mar 5, 2025 Learn more about Tenax Therapeutics (formerly Oxygen Biotherapeutics)'s company details, contact information, competitors, and more. Find accurate contact data …See details»
Investor FAQs | Tenax Therapeutics - investors.tenaxthera.com
Find answers to common investor questions about Tenax TherapeuticsSee details»
News Releases | Tenax Therapeutics
Mar 5, 2025 View Tenax Therapeutics releases, including company news, investor relations information and more.See details»
Tenax Therapeutics Announces CEO Transition and $10 Million …
Jul 7, 2021 – Anthony DiTonno Retires from Tenax; Christopher Giordano Appointed as CEO – Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company that address …See details»
Tenax Therapeutics, Inc. Expands Board of Directors | Tue, …
For more information, visit www.tenaxthera.com . About Levosimendan Levosimendan is a calcium sensitizer that works through a unique triple mechanism of action. It initially was …See details»
Contact Us – Tenax
Name Email Address Subject Message Alternative: 101 Glen Lennox Drive, Suite 300 Chapel Hill, NC 27517 [email protected]See details»
Careers – Tenax - tenaxthera.com
There are no approved drugs to treat PH-HFpEF. We’re looking for people who want to change that, and potentially help millions of patients. Explore open positions below, and if you have …See details»
SEC Filings | Tenax Therapeutics - investors.tenaxthera.com
Jun 17, 2025 View financial statements and other formal documents submitted to the U.S. Securities and Exchange Commission (SEC) for Tenax TherapeuticsSee details»
Clinical Trials – Tenax - tenaxthera.com
Apr 19, 2024 We believe levosimendan’s mechanism of action may be uniquely suited to treating PH-HFpEF. The active drug comes with a well-known safety profile established over …See details»